Dr. Reddy's Laboratories RDY announced today that it has
launched Montelukast Sodium Oral Granules, a bioequivalent generic
version of Singulair® (montelukast sodium) oral granules in the US
market on September, 26, 2012, following the approval by the United
States Food & Drug Administration (USFDA) of Dr.Reddy's ANDA for
Montelukast Sodium Oral Granules.
The Singulair® Oral Granules brand had U.S. sales
of approximately $61 million for the most recent twelve months ending
July 2012 according to IMS Health*.
Dr. Reddy's Montelukast Sodium Oral Granules in 4 mg are available in
unit dosage package of 30.
DisclaimerThis press release includes forward-looking
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in